<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438812</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS14-CT10-16</org_study_id>
    <nct_id>NCT03438812</nct_id>
  </id_info>
  <brief_title>Dehydroepiandrosterone Maintain Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders</brief_title>
  <official_title>The Role of Dehydroepiandrosterone in the Maintenance of Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether the DHEA supplementation could improve mitochondrial quality in poor
      ovarian responders
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who underwent in vitro fertilization (IVF) treatment participated, including normal
      ovarian responders (NORs) and poor ovarian responders (PORs). PORs were assigned to receive
      DHEA supplementation or not before the IVF cycle. For all patients, cumulus cells (CCs) were
      obtained after oocyte retrieval. In the CCs, mRNA expression of mitochondria-related genes
      was measured. To compare the mRNA expression of mitochondria-related genes in the CCs among
      the three groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">October 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mitochondria related genes expression</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>cumulus cells genes expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oocytes</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>retrieved oocytes in number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embryos</measure>
    <time_frame>numbers will be confirmed 3 days after fertilization</time_frame>
    <description>day 3 embryos in number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>pregnancy will be confirmed 4 weeks after embryo transfer</time_frame>
    <description>clinical pregnancy rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Poor Responders</condition>
  <condition>Dehydroepiandrosterone</condition>
  <arm_group>
    <arm_group_label>Poor ovarian responders with DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who meet the Bologna criteria receive dehydroepiandrosterone (DHEA, 90 mg daily for two months at least) supplementation prior to the IVF cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor ovarian responders</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women who meet the Bologna criteria undergo the IVF cycle without pretreatment with DHEA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal ovarian responders</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women who do not meet the Bologna criteria and have normal ovarian response to ovarian stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dehydroepiandrosterone (DHEA)</intervention_name>
    <description>Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.</description>
    <arm_group_label>Poor ovarian responders with DHEA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poor ovarian responders met the Bologna criteria, having at least two of the three
             following features: (1) advanced maternal age (≥ 40 years) or any other risk factor
             for POR, (2) a previous POR (≤ 3 oocytes with a conventional stimulation protocol),
             and (3) an abnormal ovarian reserve test. An abnormal ovarian reserve test was defined
             as antral follicle counts (AFC) &lt; 5 or anti-Müllerian hormone (AMH) &lt; 1 ng/mL in this
             study.

          -  Normal ovarian responders met the following criteria: (1) AFCs ≥ 5 or AMH ≥ 1 ng/mL
             and (2) the number of retrieved oocytes was between 5 and 15.

        Exclusion Criteria:

          -  previous oophorectomy

          -  exposure to cytotoxic or pelvic irradiation for malignancy

          -  positive screening for recurrent pregnancy loss (chromosome mapping, antinuclear
             antibodies, extractable nuclear antigens, antiphospholipid antibodies, thrombophilic
             screening)

          -  any other sensitizing or ovarian stimulating therapy during the previous 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuan-Hao Tsui, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li-Te Lin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvatore Giovanni Vitale, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Messina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Te Lin, Ph.D.</last_name>
    <phone>+886-7-3422121</phone>
    <phone_ext>4012</phone_ext>
    <email>litelin1982@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kuan-Hao Tsui, Ph.D.</last_name>
    <phone>+886-7-3422121</phone>
    <phone_ext>4014</phone_ext>
    <email>khtsui60@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuan-Hao Tsui, Ph.D.</last_name>
      <phone>+886-7-3422121</phone>
      <phone_ext>4014</phone_ext>
      <email>khtsui60@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Li-Te Lin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Giovanni Vitale, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuan-Hao Tsui, PhD</last_name>
      <phone>+886-7-3422121</phone>
      <phone_ext>4014</phone_ext>
      <email>khtsui60@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Li-Te Lin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Giovanni Vitale, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <reference>
    <citation>Lin LT, Tsui KH, Wang PH. Clinical application of dehydroepiandrosterone in reproduction: A review of the evidence. J Chin Med Assoc. 2015 Aug;78(8):446-53. doi: 10.1016/j.jcma.2014.12.008. Epub 2015 Feb 20. Review.</citation>
    <PMID>25708822</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Qiu X, Gui Y, Xu Y, Li D, Wang L. Dehydroepiandrosterone improves the ovarian reserve of women with diminished ovarian reserve and is a potential regulator of the immune response in the ovaries. Biosci Trends. 2015 Dec;9(6):350-9. doi: 10.5582/bst.2015.01154. Review.</citation>
    <PMID>26781792</PMID>
  </reference>
  <reference>
    <citation>Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2015 Nov 26;(11):CD009749. doi: 10.1002/14651858.CD009749.pub2. Review.</citation>
    <PMID>26608695</PMID>
  </reference>
  <reference>
    <citation>Tsui KH, Lin LT, Horng HC, Chang R, Huang BS, Cheng JT, Wang PH. Gene expression of cumulus cells in women with poor ovarian response after dehydroepiandrosterone supplementation. Taiwan J Obstet Gynecol. 2014 Dec;53(4):559-65. doi: 10.1016/j.tjog.2014.09.003.</citation>
    <PMID>25510701</PMID>
  </reference>
  <reference>
    <citation>Lin LT, Wang PH, Chen SN, Li CJ, Wen ZH, Cheng JT, Tsui KH. Protection of cumulus cells following dehydroepiandrosterone supplementation. Gynecol Endocrinol. 2017 Feb;33(2):100-104. doi: 10.1080/09513590.2016.1214262. Epub 2016 Aug 12.</citation>
    <PMID>27684542</PMID>
  </reference>
  <reference>
    <citation>Santos TA, El Shourbagy S, St John JC. Mitochondrial content reflects oocyte variability and fertilization outcome. Fertil Steril. 2006 Mar;85(3):584-91.</citation>
    <PMID>16500323</PMID>
  </reference>
  <reference>
    <citation>Zeng HT, Ren Z, Yeung WS, Shu YM, Xu YW, Zhuang GL, Liang XY. Low mitochondrial DNA and ATP contents contribute to the absence of birefringent spindle imaged with PolScope in in vitro matured human oocytes. Hum Reprod. 2007 Jun;22(6):1681-6. Epub 2007 Apr 20.</citation>
    <PMID>17449512</PMID>
  </reference>
  <reference>
    <citation>Lee SK, Zhao MH, Kwon JW, Li YH, Lin ZL, Jin YX, Kim NH, Cui XS. The association of mitochondrial potential and copy number with pig oocyte maturation and developmental potential. J Reprod Dev. 2014 Apr 24;60(2):128-35. Epub 2014 Feb 4.</citation>
    <PMID>24492657</PMID>
  </reference>
  <reference>
    <citation>Zhang M, Niu W, Wang Y, Xu J, Bao X, Wang L, Du L, Sun Y. Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis. J Assist Reprod Genet. 2016 Aug;33(8):981-91. doi: 10.1007/s10815-016-0713-5. Epub 2016 Apr 19. Review.</citation>
    <PMID>27094195</PMID>
  </reference>
  <reference>
    <citation>Alexaki VI, Charalampopoulos I, Panayotopoulou M, Kampa M, Gravanis A, Castanas E. Dehydroepiandrosterone protects human keratinocytes against apoptosis through membrane binding sites. Exp Cell Res. 2009 Aug 1;315(13):2275-83. doi: 10.1016/j.yexcr.2009.04.006. Epub 2009 Apr 18.</citation>
    <PMID>19379733</PMID>
  </reference>
  <reference>
    <citation>Liu D, Si H, Reynolds KA, Zhen W, Jia Z, Dillon JS. Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Galphai protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinology. 2007 Jul;148(7):3068-76. Epub 2007 Mar 29.</citation>
    <PMID>17395704</PMID>
  </reference>
  <reference>
    <citation>Charalampopoulos I, Tsatsanis C, Dermitzaki E, Alexaki VI, Castanas E, Margioris AN, Gravanis A. Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acad Sci U S A. 2004 May 25;101(21):8209-14. Epub 2004 May 17.</citation>
    <PMID>15148390</PMID>
  </reference>
  <reference>
    <citation>Ding X, Wang D, Li L, Ma H. Dehydroepiandrosterone ameliorates H2O2-induced Leydig cells oxidation damage and apoptosis through inhibition of ROS production and activation of PI3K/Akt pathways. Int J Biochem Cell Biol. 2016 Jan;70:126-39. doi: 10.1016/j.biocel.2015.11.018. Epub 2015 Nov 28.</citation>
    <PMID>26643608</PMID>
  </reference>
  <reference>
    <citation>Patel MA, Katyare SS. Effect of dehydroepiandrosterone (DHEA) treatment on oxidative energy metabolism in rat liver and brain mitochondria. A dose-response study. Clin Biochem. 2007 Jan;40(1-2):57-65. Epub 2006 Sep 14.</citation>
    <PMID>17052700</PMID>
  </reference>
  <reference>
    <citation>Patel MA, Katyare SS. Treatment with dehydroepiandrosterone (DHEA) stimulates oxidative energy metabolism in the cerebral mitochondria. A comparative study of effects in old and young adult rats. Neurosci Lett. 2006 Jul 10;402(1-2):131-6. Epub 2006 Apr 19.</citation>
    <PMID>16630690</PMID>
  </reference>
  <reference>
    <citation>Boucret L, Chao de la Barca JM, Morinière C, Desquiret V, Ferré-L'Hôtellier V, Descamps P, Marcaillou C, Reynier P, Procaccio V, May-Panloup P. Relationship between diminished ovarian reserve and mitochondrial biogenesis in cumulus cells. Hum Reprod. 2015 Jul;30(7):1653-64. doi: 10.1093/humrep/dev114. Epub 2015 May 20.</citation>
    <PMID>25994667</PMID>
  </reference>
  <reference>
    <citation>Ogino M, Tsubamoto H, Sakata K, Oohama N, Hayakawa H, Kojima T, Shigeta M, Shibahara H. Mitochondrial DNA copy number in cumulus cells is a strong predictor of obtaining good-quality embryos after IVF. J Assist Reprod Genet. 2016 Mar;33(3):367-371. doi: 10.1007/s10815-015-0621-0. Epub 2016 Jan 9.</citation>
    <PMID>26749386</PMID>
  </reference>
  <reference>
    <citation>Tsai HD, Hsieh YY, Hsieh JN, Chang CC, Yang CY, Yang JG, Cheng WL, Tsai FJ, Liu CS. Mitochondria DNA deletion and copy numbers of cumulus cells associated with in vitro fertilization outcomes. J Reprod Med. 2010 Nov-Dec;55(11-12):491-7.</citation>
    <PMID>21291035</PMID>
  </reference>
  <reference>
    <citation>Au HK, Yeh TS, Kao SH, Tzeng CR, Hsieh RH. Abnormal mitochondrial structure in human unfertilized oocytes and arrested embryos. Ann N Y Acad Sci. 2005 May;1042:177-85.</citation>
    <PMID>15965061</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2018</study_first_submitted>
  <study_first_submitted_qc>February 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>February 17, 2018</last_update_submitted>
  <last_update_submitted_qc>February 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Li-Te Lin</investigator_full_name>
    <investigator_title>Visiting Staff, Department of Obstetrics and Gynecology, Principal Investigator, Clinical Lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

